Cancer drug safety study tracks patients for years after initial treatment

NCT ID NCT03340506

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study continues to monitor patients who have already completed previous cancer treatment studies with dabrafenib and/or trametinib. It tracks 100 patients with various cancers including melanoma and lung cancer to understand the long-term safety of these medications. The goal is to provide continued access to treatment for patients who are benefiting while carefully watching for any side effects over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States
Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact
James Cancer Hospital and Solove Research Institute Ohio State
COMPLETED

Columbus, Ohio, 43210, United States
Mary Crowley Cancer Research
COMPLETED

Dallas, Texas, 75251, United States
National Institute Of Health
RECRUITING

Bethesda, Maryland, 20892, United States

Contact

Contact Email: •••••@•••••
Novartis Investigative Site
COMPLETED

Caba, Buenos Aires, C1121ABE, Argentina
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Innsbruck, Tyrol, 6020, Austria
Novartis Investigative Site
COMPLETED

Beijing, 100036, China
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Copenhagen, DK-2100, Denmark
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Lyon, 69373, France
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Nantes, 44093, France
Novartis Investigative Site
COMPLETED

Paris, 75970, France
Novartis Investigative Site
COMPLETED

Villejuif, 94800, France
Novartis Investigative Site
COMPLETED

Mannheim, Baden-Wurttemberg, 68305, Germany
Novartis Investigative Site
COMPLETED

Berlin, 13353, Germany
Novartis Investigative Site
COMPLETED

Hamburg, 20246, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Heidelberg, 69120, Germany
Novartis Investigative Site
COMPLETED

Debrecen, Hajdu Bihar Megye, 4032, Hungary
Novartis Investigative Site
COMPLETED

Budapest, H 1122, Hungary
Novartis Investigative Site
COMPLETED

Kashiwa, Chiba, 2778577, Japan
Novartis Investigative Site
COMPLETED

Chuo Ku, Tokyo, 1040045, Japan
Novartis Investigative Site
COMPLETED

Rotterdam, South Holland, 3015 GD, Netherlands
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Utrecht, 3584 CX, Netherlands
Novartis Investigative Site
RECRUITING

Barcelona, 08035, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28040, Spain
Novartis Investigative Site
COMPLETED

Madrid, 28041, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28050, Spain
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Songkhla, Hat Yai, 90110, Thailand

Conditions

Explore the condition pages connected to this study.

HIGH GRADE GLIOMA MELANOMA NON SMALL CELL LUNG CANCER RARE CANCERS SOLID TUMOR